Rubeola Virus ImmunomodulatorThis page contains information on Rubeola Virus Immunomodulator for veterinary use.
The information provided typically includes the following:
- Rubeola Virus Immunomodulator Indications
- Warnings and cautions for Rubeola Virus Immunomodulator
- Direction and dosage information for Rubeola Virus Immunomodulator
Rubeola Virus ImmunomodulatorThis treatment applies to the following species:
This product license is conditional.
Efficacy and potency test studies in progress.
CompositionAn inactivated rubeola virus combined with histamine phosphate in physiological saline. Contains phenol as a preservative.
GENERAL INFORMATION: RVI acts to modify the immune and inflammatory responses to alleviate Chronic Myofascial Inflammation and its associated problems in the equine.
Discussion: T-lymphocytes, including suppressor T-cells, significantly modulate the immune response. Unfortunately these cells are very sensitive to insult, whether from stress, dietary changes, infection, or environmental toxins. These suppressor T-cells function by controlling B-cells (the antibody producers), cytotoxic cells, and helper T-cells from over-responding to insults. Unless controlled, this over response could result in an immune response to auto or self antigens. Evidence indicates an auto immune component to chronic myofascial inflammation and myositis. Studies reflect a decrease in suppressor T-cell function, although not necessarily a decrease in absolute number of T-cells. RVI acts by specifically modulating suppressor T-cell function in a controlled fashion to allow re-establishment of the normal balance between various subpopulations of T- and B-lymphocytes. This will aid in the healing process leading to the decrease or elimination of myofascial inflammation in the affected animals.
Rubeola Virus Immunomodulator Indications
For treatment of Chronic Myofascial Inflammation (Myosins) in the equine.
ADMINISTRATION AND DOSAGE: Inject 2 ml. subcutaneously in neck of horse daily regardless of weight or age for three to six days or until the desired clinical condition is observed. In severe cases, daily injection may be required until the horse recovers. Maintenance doses and frequency will depend on the individual animal but may vary from one dose every other day to one dose a week or even every two weeks. CARE SHOULD BE EXERCISED TO ENSURE THAT THE INJECTION IS DELIVERED SUBCUTANEOUSLY.
Each 2 ml. dose contains 0.1 mcg. of neomycin.
Rubeola Virus Immunomodulator Caution
Store at 2° - 7° C (35° - 45° F). Protect from freezing. Contains phenol as a preservative. Rare transient local reactions may occur at the injection site but should subside within 24 hours. NOT FOR USE IN HORSES INTENDED FOR FOOD.
*Also referred to as RVI.
1. Michael B. Mathews and Robert M. Bernstein (1983) Myositis autoantibody inhibits histidyl-tRNA synthetase: a model for autoimmunity, Nature, Vol. 304. p. 177-179.
2. F.W. Miller, L.A. Love, B.A. Barbieri, S.E. Balow, and P.H. Plotz. (1990) Lymphocyte activation markers in idiopathic myostitis; changes with disease activity and differences among clinical and autoantibody subgroups. Clin. Exp. lmmunol. Vol. 81, p. 373-379.
How Supplied12 x 12 ml. six dose vials.
U. S. Veterinary License No. 385
EUDAEMONIC CORPORATION, 7031 No. 16th Street, Omaha, Nebraska 68112
NAC No.: 1404001.1
7031 NORTH 16TH STREET, P.O. BOX 594, OMAHA, NE, 68112
|Every effort has been made to ensure the accuracy of the Rubeola Virus Immunomodulator information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the US product label or package insert.|
Copyright © 2017 North American Compendiums. Updated: 2017-02-06